MET and colonic neoplasm: RTKs, including c-Met, have been considered as potential therapeutic targets in numerous cancers, such as HCC (Bouattour et al., 2018), colon cancer (Qian et al., 2009), head and neck cancer (Arnold et al., 2017), lung cancer (Miranda et al., 2018) and glioblastoma (Cruickshanks et al., 2017).